Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK130 and AK112 in Advanced Pancreatic Cancer
NCT07114315Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lucorafusp alfa in pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Akeso, Inc. Primary endpoints: Number of subjects with adverse events and Objective Response Rate at 2 years. Started Sep 2025; status: recruiting.
02
Drugs
lucorafusp alfa
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07114315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07114315.